These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27306777)

  • 1. Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma.
    Kim HJ; Phak JH; Kim WC
    Radiat Oncol J; 2016 Dec; 34(4):260-264. PubMed ID: 27306777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e342-e347. PubMed ID: 26846353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer.
    Lin YW; Lin LC; Lin KL
    Front Oncol; 2014; 4():278. PubMed ID: 25401085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.
    Davis J; Sharma S; Shumway R; Perry D; Bydder S; Simpson CK; D'Ambrosio D
    Cureus; 2015 Dec; 7(12):e395. PubMed ID: 26798571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.
    Bolzicco G; Favretto MS; Satariano N; Scremin E; Tambone C; Tasca A
    BMC Urol; 2013 Oct; 13():49. PubMed ID: 24134138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
    Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients.
    Pontoriero A; Iatì G; Mondello S; Midili F; Siragusa C; Brogna A; Ielo I; Anastasi G; Magno C; Pergolizzi S; De Renzis C
    Technol Cancer Res Treat; 2016 Feb; 15(1):179-85. PubMed ID: 25586517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer.
    Oliai C; Lanciano R; Sprandio B; Yang J; Lamond J; Arrigo S; Good M; Mooreville M; Garber B; Brady LW
    J Radiat Oncol; 2013 Mar; 2(1):63-70. PubMed ID: 23504305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer.
    Lee SH; Kim HJ; Kim WC
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):388-395. PubMed ID: 27461444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
    Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
    Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Prostate Int; 2015 Dec; 3(4):118-22. PubMed ID: 26779457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy with CyberKnife
    Borzillo V; Scipilliti E; Pezzulla D; Serra M; Ametrano G; Quarto G; Perdonà S; Rossetti S; Pignata S; Crispo A; Di Gennaro P; D'Alesio V; Arrichiello C; Buonanno F; Mercogliano S; Russo A; Tufano A; Di Franco R; Muto P
    Front Oncol; 2023; 13():1270498. PubMed ID: 38023175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01).
    Park Y; Park HJ; Jang WI; Jeong BK; Kim HJ; Chang AR
    Radiat Oncol; 2018 Nov; 13(1):230. PubMed ID: 30470253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.
    Dixit A; Tang C; Bydder S; Kedda MA; Vosikova E; Bharat C; Gill S
    J Med Radiat Sci; 2017 Sep; 64(3):180-187. PubMed ID: 28271639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
    Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
    Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
    King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer.
    Phak JH; Kim HJ; Kim WC
    Prostate Int; 2016 Mar; 4(1):25-9. PubMed ID: 27014661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study.
    Jorgo K; Polgar C; Stelczer G; Major T; Gesztesi L; Agoston P
    Radiol Oncol; 2021 Jul; 55(4):474-481. PubMed ID: 34253001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study.
    Katz AJ; Kang J
    Front Oncol; 2014; 4():240. PubMed ID: 25229051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.